Cancer
Mouse studies suggest combining the c-MET inhibitor capmatinib with immunotherapies could help treat melanoma, breast and colorectal cancers. In mouse models of c-MET-dependent and -independent melanoma, adoptive transfer of melanoma antigen-targeting T cells, the generic chemotherapy cyclophosphamide and the c-Met inhibitor capmatinib increased survival compared with adoptive T cell transfer of immunotherapy plus cyclophosphamide. In mouse models of melanoma, the combination of an anti-PD-1 antibody, the innate immune activators CpG and poly(I:C) and capmatinib increased survival compared with the anti-PD-1 antibody plus immune activators. In mouse models of colon and breast cancer, the anti-PD-1 antibody plus capmatinib increased survival compared with the antibody alone. Next steps could include clinical testing of capmatinib plus immunotherapies in melanoma, breast cancer and colorectal cancer patients...
BCIQ Company Profiles